DOI: No DOI assigned
Dr. Farhana Selina MBBS, MD (Anesthesia, Analgesia & ICU) Fellowship in Neuroanesthesia (Japan) Associate Professor, Department of Anesthesiology, Sylhet Women’s Medical College Hospital. Email: farhana.selina@gmail.com
The coronavirus disease due to severe acute respiratory syndrome 2 (SARS-CoV 2) was allegedly originated from the city of Wuhan of China and eventually spread in to all over the world. World Health Organization (WHO) has declared it pandemic on February 11, 2020. At the middle of July 2020, the total affected patient number raised to more than 14 million and more than 6 lac people died of this disease across more than 200 countries and territories. According to studies nearly 14% patients became severe and overall mortality was 7%. Most of COVID-19 patients (80.9%) were reported as mild cases whereas 13.8% cases were severely ill and 4.7% were critical. Most of the cases (86.6%) were within the age group of 30 to 70 years. Patients with co-existing diseases showed a higher mortality rate. The common comorbidities were cardiovascular disease (10.5%), diabetes mellitus (7.3%), chronic respiratory disease (6.3%), hypertension (6.0%) and cancer (5.6%).1 A single-centered study revealed the critical care patient’s complications for COVD-19. Most of the patients admitted in to the intensive care unit (ICU) developed organ failures. More than twothird patient (67%) patients developed acute respiratory distress syndrome (ARDS) and more than one-fourth (29%) patients had acute kidney injury (AKI) and liver dysfunction. Cardiac injury was detected in 23% patients whereas 2% cases had pneumothorax.1